Cancer Biosimilars Market
完整報告名稱與涵蓋範圍
Cancer Biosimilars Market Size, Share & Trends Analysis Report By Type (Lung Cancer, Breast cancer, Ovarian cancer, Prostate cancer, Lymphoma, Others), By Distribution Channel, By Drug Class, By Route of Administration, Region And Segment Forecasts, 2023-2031
報告摘要
Across the 2023 to 2031 projection horizon, the worldwide Cancer Biosimilars Market is projected to register a CAGR of 20.0%.
Cancer Biosimilars encompasses approved by respective regulatory bodies because of its clinical similarity to already approved biological products. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Market momentum is fueled by growing interest in advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region projected to deliver the strongest growth trajectory through the forecast period, fueled by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cancer Biosimilars Market Snapshot
Chapter 4. Global Cancer Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Biologic Class Estimates & Trend Analysis
5.1. By Biologic Class & Market Share, 2021 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Biologic Class:
5.2.1. Bevacizumab
5.2.2. Rituximab
5.2.3. Trastuzumab
5.2.4. Filgrastim
5.2.5. Pegfilgrastim
5.2.6. Denosumab
5.2.7. Others (Products approved in developing countries & pipeline products)
Chapter 6. Market Segmentation 2: By Type Estimates & Trend Analysis
6.1. By Type & Market Share, 2021 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Type:
6.2.1. Lung Cancer
6.2.2. Breast cancer
6.2.3. Ovarian cancer
6.2.4. Prostate cancer
6.2.5. Lymphoma
6.2.6. Others
Chapter 7. Market Segmentation 3: By Drug Class Estimates & Trend Analysis
7.1. By Drug Class & Market Share, 2021 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Drug Class:
7.2.1. G-CSF
7.2.2. Monoclonal Antibody
Chapter 8. Market Segmentation 4: By Route of Administration Estimates & Trend Analysis
8.1. By Route of Administration & Market Share, 2021 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Route of Administration:
8.2.1. Intravenous
8.2.2. Subcutaneous
8.2.3. Others
Chapter 9. Market Segmentation 5: By Distribution Channel Estimates & Trend Analysis
9.1. By Distribution Channel & Market Share, 2021 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Distribution Channel:
9.2.1. Hospital Pharmacy
9.2.2. Retail Pharmacy
9.2.3. Online Pharmacy
9.2.4. Others
Chapter 10. Cancer Biosimilars Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.1.2. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.1.3. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.1.4. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.1.5. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.1.6. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts by country, 2025 - 2034
10.2. Europe
10.2.1. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.2.2. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.2.3. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.2.4. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.2.5. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.2.6. Europe Cancer Biosimilars Market revenue (US$ Million) by country, 2025 - 2034
10.3. Asia Pacific
10.3.1. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.3.2. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.3.3. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.3.4. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.3.5. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.3.6. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) by country, 2025 - 2034
10.4. Latin America
10.4.1. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.4.2. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.4.3. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.4.4. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.4.5. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.4.6. Latin America Cancer Biosimilars Market revenue (US$ Million) by country, (US$ Million) 2025 - 2034
10.5. Middle East & Africa
10.5.1. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.5.2. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.5.3. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.5.4. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.5.5. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.5.6. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) by country, (US$ Million) 2025 - 2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Mylan
11.2.2. Amgen
11.2.3. Pfizer
11.2.4. Celltrion
11.2.5. Samsung Bioepis
11.2.6. Bio-Thera Solutions
11.2.7. Sandoz (Novartis)
11.2.8. Teva
11.2.9. Coherus BioSciences
11.2.10. CuraTeQ Biologics
11.2.11. Accord Healthcare
11.2.12. Allergan
11.2.13. Biocon
11.2.14. Merck
11.2.15. Accord BioPharma
11.2.16. Accord Healthcare S.L.U.
11.2.17. AffaMed
11.2.18. Biosimilar Collaborations Ireland Limited
11.2.19. Dr. Reddy's
11.2.20. Henlius
11.2.21. Intas
11.2.22. Mabxience
11.2.23. Nippon Kayaku
11.2.24. Sandoz GmbH
11.2.25. Amgen Inc.
11.2.26. Amneal Pharmaceuticals, Inc.
11.2.27. Betta Pharmaceuticals/Beijing Mabworks
11.2.28. Bio-Thera Solutions, Ltd.
11.2.29. Celltrion, Inc.
11.2.30. Cipla
11.2.31. Dr. Reddy's Laboratories
11.2.32. FGK Representative Service GmbH
11.2.33. Hetero
11.2.34. Innovent Biologics
11.2.35. mAbxience Holding, S.L.
11.2.36. Outlook Therapeutics Limited
11.2.37. Pfizer Inc.
11.2.38. Roche Registration GmbH
11.2.39. Samsung Bioepis NL B.V.
11.2.40. Sandoz Inc.
11.2.41. Shanghai Henlius Biotech
11.2.42. STADA Arzneimittel AG
11.2.43. TOT BIOPHARM
11.2.44. AstraZeneca PLC
11.2.45. Samsung Bioepis Co., Ltd.
11.2.46. Organon & Co.
11.2.47. Other Prominent Player
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們